<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03228667</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-02-17</org_study_id>
    <nct_id>NCT03228667</nct_id>
  </id_info>
  <brief_title>QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors</brief_title>
  <official_title>QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies&#xD;
      in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint&#xD;
      inhibitors. All patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1&#xD;
      checkpoint inhibitor plus N-803 for up to 17 cycles. Each cycle is six weeks in duration.&#xD;
      Some patients who experience disease progression while on study in Cohorts 1-4 may roll over&#xD;
      into Cohort 5 and receive combination therapy with a PD-1/PD-L1 checkpoint inhibitor, N-803,&#xD;
      and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles. Each cycle is six weeks&#xD;
      in duration. All patients will receive N-803 once every 3 weeks. Patients will also receive&#xD;
      the same checkpoint inhibitor that they received during their previous therapy. Radiologic&#xD;
      evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2&#xD;
      years, or until the patient experiences confirmed progressive disease or unacceptable&#xD;
      toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's&#xD;
      best interest to continue treatment. Patients will be followed for disease progression,&#xD;
      post-therapies, and survival through 24 months past administration of the first dose of study&#xD;
      drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time from first treatment to death resulting from cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time from first treatment to death resulting from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time to response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>Assess duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Assess incidence of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>24 months</time_frame>
    <description>Compare changes in QOL scores from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time from first treatment to disease progression or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Microsatellite Instability</condition>
  <condition>Mismatch Repair Deficiency</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.&#xD;
1a - Non-small cell lung cancer&#xD;
1b - Small cell lung cancer&#xD;
1c - Urothelial carcinoma&#xD;
1d - Head and neck squamous cell carcinoma&#xD;
1e - Merkel cell carcinoma&#xD;
1f - Melanoma&#xD;
1g - Renal cell carcinoma&#xD;
1h - Gastric cancer&#xD;
1i - Cervical cancer&#xD;
1j - Hepatocellular carcinoma&#xD;
1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Pembrolizumab</intervention_name>
    <description>Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Nivolumab</intervention_name>
    <description>Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Atezolizumab</intervention_name>
    <description>Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Avelumab</intervention_name>
    <description>Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Durvalumab</intervention_name>
    <description>Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Pembrolizumab + PD-L1 t-haNK</intervention_name>
    <description>Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Nivolumab + PD-L1 t-haNK</intervention_name>
    <description>Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Atezolizumab + PD-L1 t-haNK</intervention_name>
    <description>Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Avelumab + PD-L1 t-haNK</intervention_name>
    <description>Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-803 + Durvalumab + PD-L1 t-haNK</intervention_name>
    <description>Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent&#xD;
&#xD;
             • Voluntary written informed consent and HIPAA authorization and agree to comply with&#xD;
             all protocol-specified procedures and follow-up evaluations&#xD;
&#xD;
          2. Target Population&#xD;
&#xD;
               1. Cohort 1 will enroll patients who have Investigator-assessed disease progression&#xD;
                  on or after single-agent checkpoint inhibitor therapy after experiencing an&#xD;
                  initial response (ie, Investigator-assessed CR or PR) while taking checkpoint&#xD;
                  inhibitor therapy. Patients will be enrolled into distinct cohorts (1a-1k) based&#xD;
                  on cancer type.&#xD;
&#xD;
                  Patients must have been treated with checkpoint inhibitor therapy after&#xD;
                  progressing on SoC therapy for their disease, as per FDA indication detailed&#xD;
                  below:&#xD;
&#xD;
                    -  1a - For metastatic squamous or nonsquamous NSCLC with progression on or&#xD;
                       after nivolumab, pembrolizumab, or atezolizumab, initial SoC therapy must&#xD;
                       have been for disease with progression on or after one prior platinum&#xD;
                       doublet-based chemotherapy regimen. Patients with EGFR or ALK genomic tumor&#xD;
                       aberrations should have had disease progression on FDA-approved targeted&#xD;
                       therapy for these aberrations prior to receiving checkpoint inhibitor.&#xD;
&#xD;
                    -  1b - For metastatic SCLC with disease progression on or after nivolumab or&#xD;
                       pembrolizumab monotherapy, initial SoC treatment must have been for disease&#xD;
                       with progression after platinum-based chemotherapy and at least one other&#xD;
                       line of therapy prior to receiving checkpoint.&#xD;
&#xD;
                    -  1c - Locally advanced or metastatic urothelial carcinoma as follows:&#xD;
&#xD;
                    -  For patients with progression on or after nivolumab monotherapy, initial SoC&#xD;
                       must have been for disease with progression on or after platinum-based&#xD;
                       chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with&#xD;
                       platinum-based chemotherapy.&#xD;
&#xD;
                    -  For patients with disease progression on or after pembrolizumab, initial SoC&#xD;
                       therapy may have been for locally advanced or metastatic urothelial&#xD;
                       carcinoma ineligible for cisplatin-containing chemotherapy with PD-L1 tumor&#xD;
                       expression of CPS ≥ 10 (as determined by FDA-approved test), OR metastatic&#xD;
                       urothelial carcinoma not eligible for any platinum-containing chemotherapy&#xD;
                       regardless of PD-L1 status, OR locally advanced or metastatic urothelial&#xD;
                       carcinoma with progression on or after platinum-based chemotherapy or within&#xD;
                       12 months of neoadjuvant or adjuvant treatment with platinum-based&#xD;
                       chemotherapy.&#xD;
&#xD;
                    -  For patients with disease progression on or after atezolizumab, initial SoC&#xD;
                       therapy may have been for locally advanced or metastatic urothelial&#xD;
                       carcinoma not eligible for cisplatin-based chemotherapy that expresses PD-L1&#xD;
                       (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the&#xD;
                       tumor area, as determined by an FDA-approved test), OR not eligible for&#xD;
                       cisplatin-based chemotherapy regardless of PD-L1 status, OR with progression&#xD;
                       on or after platinum-based chemotherapy or within 12 months of neoadjuvant&#xD;
                       or adjuvant treatment with platinum-based chemotherapy.&#xD;
&#xD;
                    -  For patients with disease progression on or after avelumab, initial SoC&#xD;
                       therapy may have been for locally advanced or metastatic urothelial&#xD;
                       carcinoma with progression on or after platinum-based chemotherapy or within&#xD;
                       12 months of neoadjuvant or adjuvant treatment with platinum-based&#xD;
                       chemotherapy.&#xD;
&#xD;
                    -  For patients with disease progression on or after durvalumab, initial SoC&#xD;
                       therapy may have been for disease with progression on or after&#xD;
                       platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant&#xD;
                       treatment with platinum-based chemotherapy.&#xD;
&#xD;
                    -  1d - Recurrent or metastatic HNSCC as follows:&#xD;
&#xD;
                    -  For patients with disease progression on or after nivolumab monotherapy,&#xD;
                       initial SoC treatment must have been for disease with progression on or&#xD;
                       within 6 months of a platinum-based therapy administered in the adjuvant,&#xD;
                       neoadjuvant, primary (unresectable locally advanced), or metastatic setting.&#xD;
&#xD;
                    -  For patients with disease progression on or after pembrolizumab monotherapy,&#xD;
                       initial SoC treatment must have been for disease with progression on or&#xD;
                       after platinum-based chemotherapy, or after platinum-based chemotherapy&#xD;
                       administered as part of induction, concurrent, or adjuvant therapy.&#xD;
&#xD;
                    -  1e - For histologically confirmed metastatic MCC with progression on or&#xD;
                       after avelumab or pembrolizumab, initial SoC therapy must have been for&#xD;
                       disease with progression on or after chemotherapy administered for distant&#xD;
                       metastatic disease; OR recurrent locally advanced or metastatic MCC not&#xD;
                       treated with prior systemic therapy for advanced disease.&#xD;
&#xD;
                    -  1f - Metastatic melanoma as follows:&#xD;
&#xD;
                    -  For patients with disease progression on or after nivolumab administered as&#xD;
                       a single agent, in combination with ipilimumab, or in the adjuvant setting,&#xD;
                       initial SoC treatment must have been for unresectable or metastatic melanoma&#xD;
                       with progression on or after ipilimumab treatment, and if BRAF V600 mutation&#xD;
                       positive, a BRAF inhibitor; OR BRAF V600 wild-type unresectable or&#xD;
                       metastatic melanoma previously untreated in the metastatic setting; OR&#xD;
                       previously untreated, unresectable, or metastatic melanoma not previously&#xD;
                       treated with anti-CTLA4 antibody; OR completely resected melanoma with lymph&#xD;
                       node involvement, or stage IIIB/C or stage IV metastatic disease.&#xD;
&#xD;
                    -  For patients with disease progression on or after pembrolizumab therapy,&#xD;
                       initial SoC treatment must have been for unresectable or metastatic melanoma&#xD;
                       with no prior ipilimumab, and no more than 1 prior systemic treatment for&#xD;
                       metastatic disease. Patients with BRAF V600E mutation-positive melanoma were&#xD;
                       not required to have received prior BRAF inhibitor therapy; OR unresectable&#xD;
                       or metastatic melanoma with progression, refractory to ≥ 2 doses of&#xD;
                       ipilimumab (3 mg/kg or higher) and, if BRAF V600 mutation-positive, a BRAF&#xD;
                       or MEK inhibitor, and disease progression within 24 weeks following the last&#xD;
                       dose of ipilimumab.&#xD;
&#xD;
                    -  1g - For advanced RCC with progression on or after nivolumab monotherapy,&#xD;
                       initial SoC therapy must have been for disease that progressed after 1 or 2&#xD;
                       prior anti-angiogenic therapy regimens. For intermediate or poor risk&#xD;
                       previously untreated advanced RCC, patients must have progressed on or after&#xD;
                       nivolumab + ipilimumab.&#xD;
&#xD;
                    -  1h - For recurrent locally advanced or metastatic gastric or&#xD;
                       gastroesophageal junction adenocarcinoma with progression on or after&#xD;
                       pembrolizumab, initial SoC therapy must have been for disease that&#xD;
                       progressed on or after ≥ 2 prior lines of therapy including&#xD;
                       fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate,&#xD;
                       HER2/neu-targeted therapy. Tumors must express PD-L1 (combined positive&#xD;
                       score [CPS] ≥ 1), as determined by an FDA-approved test.&#xD;
&#xD;
                    -  1i - For recurrent or metastatic cervical cancer with progression on or&#xD;
                       after pembrolizumab, initial SoC therapy must have been for disease that&#xD;
                       progressed on or after chemotherapy. Tumors must express PD-L1 (CPS ≥ 1), as&#xD;
                       determined by an FDA-approved test.&#xD;
&#xD;
                    -  1j - For HCC with progression on or after pembrolizumab, initial SoC&#xD;
                       treatment must have been for disease that progressed on or after sorafenib&#xD;
                       or intolerant to sorafenib. Patients must have had measureable disease and&#xD;
                       Child-Pugh class A liver impairment. For HCC with progression on or after&#xD;
                       nivolumab administered as a single agent or in combination with ipilimumab,&#xD;
                       initial SoC treatment must have been for histologically confirmed HCC with&#xD;
                       progression on sorafenib or intolerant to sorafenib, and Child-Pugh class A.&#xD;
&#xD;
                    -  1k -Unresectable or metastatic MSI-H or dMMR solid tumors as follows:&#xD;
&#xD;
                    -  For patients with progression on or after nivolumab administered as a single&#xD;
                       agent or in combination with ipilimumab, initial SoC therapy must have been&#xD;
                       for MSI-H or dMMR metastatic CRC with progression on or after treatment with&#xD;
                       a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.&#xD;
&#xD;
                    -  For patients with progression on or after pembrolizumab, initial SoC therapy&#xD;
                       must have been for unresectable or metastatic MSI-H or dMMR solid tumors&#xD;
                       with progression after prior treatment and no satisfactory alternative&#xD;
                       treatment options; OR unresectable or metastatic MSI-H or dMMR CRC with&#xD;
                       progression after treatment with a fluoropyrimidine, oxaliplatin, and&#xD;
                       irinotecan.&#xD;
&#xD;
               2. For cohort 2, patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥&#xD;
                  50%) and who have Investigator-assessed disease progression on a PD-1/PD-L1&#xD;
                  checkpoint inhibitor after experiencing an initial Investigator-assessed CR or PR&#xD;
                  when they received checkpoint inhibitor as a single-agent for first-line&#xD;
                  treatment.&#xD;
&#xD;
               3. For cohort 3, patients with NSCLC who had an initial Investigator-assessed CR or&#xD;
                  PR but subsequently relapsed (ie, Investigator-assessed disease progression) on&#xD;
                  maintenance PD-1/PD-L1 checkpoint inhibitor therapy when they initially received&#xD;
                  checkpoint inhibitor therapy in combination with chemotherapy as first-line&#xD;
                  treatment.&#xD;
&#xD;
               4. For cohort 4, patients with NSCLC, HNSCC, RCC, or urothelial carcinoma who are&#xD;
                  currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have&#xD;
                  Investigator-assessed disease progression after experiencing SD for at least 6&#xD;
                  months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor&#xD;
                  therapy.&#xD;
&#xD;
               5. For cohort 5, patients that have experienced disease progression by Investigator&#xD;
                  assessment per irRECIST while receiving treatment in cohorts 1-4.&#xD;
&#xD;
               6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
               7. Measurable disease by CT or MRI, as defined by RECIST 1.1, except Cohort 5, where&#xD;
                  non-measurable disease is also allowed&#xD;
&#xD;
               8. Treatment of at least 3 months (cohort 1-3) or at least 6 months (cohort 4) with&#xD;
                  checkpoint inhibitor and Investigator-assessed CR or PR (for cohorts 1-3 only) or&#xD;
                  SD (for cohort 4 only) and ≤ 6 weeks of treatment interruption (cohorts 1-4)&#xD;
                  immediately prior to study enrollment; treatment in cohort 5 must occur within 1&#xD;
                  year of discontinuation from cohorts 1-4.&#xD;
&#xD;
               9. Patients with genomic tumor aberrations should have received prior treatment with&#xD;
                  an FDA-approved targeted therapy (if available)&#xD;
&#xD;
              10. Adequate organ system function within 14 days of baseline:&#xD;
&#xD;
                    -  ANC ≥ 1500 cells/µL (≥1.5 x 10^9 cells/L)&#xD;
&#xD;
                    -  Platelets ≥ 100,000 cells/µL (≥100 x 10^9 cells/L)&#xD;
&#xD;
                    -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
                    -  Total bilirubin &lt; 1.0 x ULN&#xD;
&#xD;
                    -  AST &lt; 1.5 x ULN&#xD;
&#xD;
                    -  ALT &lt; 1.5 x ULN&#xD;
&#xD;
                    -  eGFR &gt; 45 mL/min&#xD;
&#xD;
          3. Age and Reproductive Status&#xD;
&#xD;
               1. Men and women, ≥ 18 years of age&#xD;
&#xD;
               2. Women of childbearing potential (WOCBP) must adhere to using a medically accepted&#xD;
                  method of birth control up to 28 days prior to screening and agree to continue&#xD;
                  its use during the study or be surgically sterilized (e.g., hysterectomy or tubal&#xD;
                  ligation) and males must agree to use barrier methods of birth control while on&#xD;
                  study. WOCBP must agree to use effective contraception during treatment and for&#xD;
                  at least 5 months following the last dose of study treatment.&#xD;
&#xD;
               3. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy&#xD;
                  test during Screening and a negative urine pregnancy test within 24 hours prior&#xD;
                  to first dose of study treatment (cohorts 1-4); subjects in cohort 5 must have a&#xD;
                  negative urine pregnancy test at screening and baseline. Non-childbearing is&#xD;
                  defined as greater than one year postmenopausal or surgically sterilized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target Disease Exceptions&#xD;
&#xD;
             a. Patients with CNS metastases with the following exceptions:&#xD;
&#xD;
               -  Patient untreated CNS metastases with 4 or fewer sites of disease, with no single&#xD;
                  site larger than 20mm, are eligible if they are asymptomatic and not requiring&#xD;
                  steroids at any dose. Patients with asymptomatic CNS metastases may be treated&#xD;
                  with radiosurgery before or during therapy on trial without treatment delays.&#xD;
&#xD;
               -  Patients with treated, symptomatic CNS metastases are eligible if they are&#xD;
                  neurologically returned to baseline (except for residual signs or symptoms&#xD;
                  related to the CNS treatment) for at least 2 weeks prior to registration AND&#xD;
                  either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily&#xD;
                  prednisone (or equivalent).&#xD;
&#xD;
               -  Patients enrolling in cohort 5&#xD;
&#xD;
          2. Medical History and Concurrent Diseases&#xD;
&#xD;
               1. New York Heart Association (NYHA) Class III or IV heart failure, uncontrollable&#xD;
                  supraventricular arrhythmias, any history of a ventricular arrhythmia, or other&#xD;
                  clinical signs of severe cardiac dysfunction&#xD;
&#xD;
               2. Symptomatic congestive heart failure, unstable angina pectoris, or myocardial&#xD;
                  infarction within 6 months of enrollment&#xD;
&#xD;
               3. Known autoimmune disease requiring active treatment. Subjects with a condition&#xD;
                  requiring systemic treatment with either corticosteroids (&gt;10 mg daily prednisone&#xD;
                  equivalent) or other immunosuppressive medications within 14 days of enrollment&#xD;
                  are excluded. Inhaled or topical steroids, and adrenal replacement steroid doses&#xD;
                  &lt; 10 mg daily prednisone equivalent, are permitted in the absence of active&#xD;
                  autoimmune disease&#xD;
&#xD;
               4. History of interstitial lung disease and/or immune mediated pneumonitis.&#xD;
&#xD;
               5. Known HIV-positive&#xD;
&#xD;
               6. Active systemic infection requiring parenteral antibiotic therapy&#xD;
&#xD;
               7. Positive hepatitis C serology or active hepatitis B infection&#xD;
&#xD;
               8. Any ongoing toxicity from prior anti-cancer treatment that, in the judgement of&#xD;
                  the investigator, may interfere with study treatment. All toxicities attributed&#xD;
                  to prior anti-cancer therapy other than alopecia and fatigue must resolve to&#xD;
                  grade 1 (NCI CTCAE version 4) or baseline prior to enrollment. Eligible patients&#xD;
                  must not require more than 10 mg/day prednisone (or equivalent dose).&#xD;
&#xD;
               9. Previous malignancies (except non-melanoma skin cancers, in situ bladder cancer,&#xD;
                  in situ gastric or in situ colon cancers, in situ cervical cancers/dysplasia or&#xD;
                  breast carcinoma in situ) unless a complete remission was achieved at least 1&#xD;
                  year prior to study entry and no additional therapy is required or anticipated to&#xD;
                  be required during the study period. This exclusion does not apply to patients&#xD;
                  enrolling in cohort 5.&#xD;
&#xD;
              10. No other illness that in the opinion of the investigator would exclude the&#xD;
                  subject from participating in the study&#xD;
&#xD;
          3. Prohibited Treatments and/or Restricted Therapies&#xD;
&#xD;
               1. Patients in which treatment with PD-1/PD-L1 checkpoint inhibitor is&#xD;
                  contraindicated&#xD;
&#xD;
               2. Patients who have received another investigational agent within the previous 3&#xD;
                  months. This exclusion criteria does not apply to patients enrolling in cohort 5.&#xD;
&#xD;
          4. Sex and Reproductive Status a. Women who are pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MemorialCare Health System</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>37846</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group, Inc.</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute (Baptist Health South Florida)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Associates</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health - Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health- Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Research Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Cancer &amp; Hematology - Chub O'Reilly Cancer Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center (SCL)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Main Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg/Hanover Cancer Centers</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center/Bon Secours St. Francis Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinical Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>August 25, 2023</last_update_submitted>
  <last_update_submitted_qc>August 25, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Non-Small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Interleukin-15</keyword>
  <keyword>PD-1 Checkpoint Inhibitor</keyword>
  <keyword>ALT-803</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Avelumab</keyword>
  <keyword>Small Cell Lung Cancer (SCLC)</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma (HNSCC)</keyword>
  <keyword>Merkel Cell Carcinoma (MCC)</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Renal Cell Carcinoma (RCC)</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Hepatocellular Carcinoma (HCC)</keyword>
  <keyword>Microsatellite Instability-High (MSI-H)</keyword>
  <keyword>PD-L1 Checkpoint Inhibitor</keyword>
  <keyword>Mismatch Repair Deficient (dMMR) Solid Tumor Cancer</keyword>
  <keyword>Colorectal Cancer (CRC)</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>PD-L1 t-haNK</keyword>
  <keyword>N-803</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Opdivo</keyword>
  <keyword>Imfinzi</keyword>
  <keyword>Bavencio</keyword>
  <keyword>Tecentriq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03228667
org study id: CA-ALT-803-02-17
nct id: NCT03228667
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies
      in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint
      inhibitors. All patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1
      checkpoint inhibitor plus N-803 for up to 17 cycles. Each cycle is six weeks in duration.
      Some patients who experience disease progression while on study in Cohorts 1-4 may roll over
      into Cohort 5 and receive combination therapy with a PD-1/PD-L1 checkpoint inhibitor, N-803,
      and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles. Each cycle is six weeks
      in duration. All patients will receive N-803 once every 3 weeks. Patients will also receive
      the same checkpoint inhibitor that they received during their previous therapy. Radiologic
      evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2
      years, or until the patient experiences confirmed progressive disease or unacceptable
      toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's
      best interest to continue treatment. Patients will be followed for disease progression,
      post-therapies, and survival through 24 months past administration of the first dose of study
      drug.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Objective Response Rate
time frame: 24 months
description: Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1.
measure: Disease-specific Survival
time frame: 24 months
description: Assess time from first treatment to death resulting from cancer.
measure: Overall Survival
time frame: 24 months
description: Assess time from first treatment to death resulting from any cause.
measure: Time to Response
time frame: 24 months
description: Assess time to response
measure: Duration of Response
time frame: 24 months
description: Assess duration of response
measure: Incidence of Adverse Events
time frame: 24 months
description: Assess incidence of adverse events.
measure: Quality of Life (QOL)
time frame: 24 months
description: Compare changes in QOL scores from baseline.
measure: Progression Free Survival
time frame: 24 months
description: Assess time from first treatment to disease progression or death from any cause, whichever occurs first.
arm group label: Cohort 1
arm group type: Other
description: Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.
1a - Non-small cell lung cancer
1b - Small cell lung cancer
1c - Urothelial carcinoma
1d - Head and neck squamous cell carcinoma
1e - Merkel cell carcinoma
1f - Melanoma
1g - Renal cell carcinoma
1h - Gastric cancer
1i - Cervical cancer
1j - Hepatocellular carcinoma
1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer
arm group label: Cohort 2
arm group type: Other
description: Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
arm group label: Cohort 3
arm group type: Other
description: Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
arm group label: Cohort 4
arm group type: Experimental
description: Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
arm group label: Cohort 5
arm group type: Experimental
description: Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
intervention type: Drug
intervention name: N-803 + Pembrolizumab
description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
arm group label: Cohort 1
arm group label: Cohort 2
arm group label: Cohort 3
arm group label: Cohort 4
intervention type: Drug
intervention name: N-803 + Nivolumab
description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
arm group label: Cohort 1
arm group label: Cohort 2
arm group label: Cohort 3
arm group label: Cohort 4
intervention type: Drug
intervention name: N-803 + Atezolizumab
description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
arm group label: Cohort 1
arm group label: Cohort 4
intervention type: Drug
intervention name: N-803 + Avelumab
description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
arm group label: Cohort 1
arm group label: Cohort 4
intervention type: Drug
intervention name: N-803 + Durvalumab
description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
arm group label: Cohort 1
arm group label: Cohort 4
intervention type: Drug
intervention name: N-803 + Pembrolizumab + PD-L1 t-haNK
description: Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
arm group label: Cohort 5
intervention type: Drug
intervention name: N-803 + Nivolumab + PD-L1 t-haNK
description: Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
arm group label: Cohort 5
intervention type: Drug
intervention name: N-803 + Atezolizumab + PD-L1 t-haNK
description: Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
arm group label: Cohort 5
intervention type: Drug
intervention name: N-803 + Avelumab + PD-L1 t-haNK
description: Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
arm group label: Cohort 5
intervention type: Drug
intervention name: N-803 + Durvalumab + PD-L1 t-haNK
description: Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at ~2 x 10^9 cells/dose weekly
arm group label: Cohort 5
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma, Merkel Cell
mesh term: Carcinoma
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Colorectal Neoplasms
mesh term: Melanoma
mesh term: Carcinoma, Squamous Cell
mesh term: Carcinoma, Hepatocellular
mesh term: Stomach Neoplasms
mesh term: Uterine Cervical Neoplasms
mesh term: Carcinoma, Renal Cell
mesh term: Small Cell Lung Carcinoma
mesh term: Carcinoma, Transitional Cell
mesh term: Squamous Cell Carcinoma of Head and Neck
mesh term: Microsatellite Instability
mesh term: Pembrolizumab
mesh term: Nivolumab
mesh term: Atezolizumab
mesh term: Durvalumab
mesh term: Avelumab
mesh term: Antibodies, Monoclonal
sharing ipd: No